Get started

Biotech

I have a strong feeling... (EDSA)Hello everybody and happy new year! ❤ Major retest of breaking 6-7 years of channel Resistance. The retest after a very strong impulsive move out of the channel is forming a falling wedge with very tight price consolidation. Another plus about this stock is that it has a very low float. I like accumulation here, maybe one more chance at 3.56 I'm extremely bullish on this and see a lot of correlation with a lot of other low float biotech / pharmaceutical stocks. My thoughts on a very long term swing trade, See you at the top 🚀
NASDAQ:EDSALong
by UnknownUnicorn2319099
6
Huge upside potentialContraceptives (just like vitamins and/or other medicine and supplements) are and always be crucial, no matter what is the economic situation. This is why I'm looking at and showing you TXMD. TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their healthcare issues. We develop products to address the unique changes and challenges women experience throughout the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. Check out their website if interested in more info, I just quoted this above from there. Lately (but before the 2020 crash) this stock was in the range between $5 - $7 (much higher before) and you could make a 30-40% profit on a swing trade. But now the good side of this Covid situation and the fact that everyone was buying EV, stay at home, tech and similar popular stocks so far, is that some of the other market participants like biotech, REIT or energy didn't go so well. But now it's time for this one to regenerate too. By "now" I mean within a year or so. Realistically I see this should get to that range again, between $5 and $7 and consolidate around it, but of course it can take several brakes (profit taking) on the way up, at those levels I marked. Also it can go any higher to the $10 area or even more, we can not tell yet for sure. But right now it is way under valued and beaten down, so it is a strong buy in my opinion. And here is my "story" again: Probably I’ll post this text several times (under each ticker) that I mention below, as the meaning of the writing necessitate it. Introduction and the mindset: 8-10% of my wealth is in the US stock market, other almost 90% in real estate in Europe. As for the stocks, you got to have a diversified portfolio in my opinion. As my experience tells me you can be lucky sometimes and you also gonna be unlucky at any given time (and it’s unexpected all the time). So one can not count on luck and/or feelings (I call it being on Hope-ium). This is the reason for the need of diversification, especially in this unprecedented (word of 2020, right?) environment. Lots of analysts say the market is overvalued, stock prices are overstretched (the SPY and tech at least). I think this is partially true and it does matter sometimes, it does not matter too much other times and/or instances as you’ll see soon below. OK, too much talk already, I will show you my portfolio and talk about my ideas with numbers, entry points, targets and even risks. My past fundamental ideas (as for reputation, not a bluffer): In 2019 I only had 2 ideas, both based on my fundamental analysis and they were for investment (so, not for short term trade ideas). Tesla and Bitcoin. For TSLA my entry plan and buying advice was @ $426 in December (pre-split price, so if you are new, divide it by 5). For BTC I stated that I recon we have to wait for the beginning of 2020 (according to my plan it was most likely for about February) and buy the expected dip - according to my readings - at $5500. Of course Covid came and things got crazy, but we didn’t expect that. Lots of losses and learning, but here I share some useful thoughts and ideas. I learned technical analysis, but these fundamental ideas born according to my own research, also I didn’t know any known influencer back then. My recent/actual ideas and how to do it: I divide my stock portfolio for 5 sectors in a way that if even 3 or 4 of them fails, the other 1 or 2 will pay out so much, I wouldn’t mind and never lose. My sectors watched: 1.REIT (they will recover and pay good dividends) 2.Energy (they will recover as soon as Covid is over) 3.Commodities (we need them whatever happens) 4.Biotech (necessity too, no matter what) 5.Insurance (self explanatory). The SPY is driven by tech, so I left it out for now (with a small exception), as no need to risk now, because tech is a bit overstretched at the moment and even if it’s going way higher, my ideas will too. But if tech is not going higher, I will still make profits (hence the so called ‘K-shape recovery’). Not easy to do this in such overvalued levels but not everything is expensive and also note, that not every cheap stock is going to die off, so the main buying habit of mine is what George Gammon likes also: “I buy a dollar for fifty cents” if I may quote him here. This idea means that I buy according to the actual (and my own) valuation, plus the current stock price of the company and not according to the momentum or the horde, in other words the ‘best performers’ according to popular Youtubers, similar influencers (or the mainstream media for that matter), as history shows that the majority loses and the minority wins (at least during those crazy unprecedented times like now when soon everyone is in the stock market. The examples I analyzed: 1929, 2000, 2008). Doesn’t the 2008 example tell you that it would be wiser to be on the side of Michael Burry during the stock market rally instead of everyone else? Yeah, I know, it’s not easy and also, “this time will be different” :D But jokes aside, I believe at least in a way this time it actually could be different, the task is to understand fundamentals, think a lot and make smart decisions based on your own research. And the more you read and think, the closer you might get to some advantage and solution that will pay off highly likely in every possible scenario in the future. Why and how? A simple enough hint of mine for example is, if a stock is a ‘top performer’ that fact might actually mean it already did what we expected from it to do (otherwise why the term?), so you kind of could already be late, but you would never know. This is when FOMO comes in to play, beware! Sure, you can be lucky and participate in a bubble just like how it was with Yahoo in 1999-2000 but only afterwards (years later) could you for sure realize that it wasn’t a good idea to buy in around 1999 as you didn’t sell at the top (2nd of January, 2000) did you? Even though the “long term fundamentals” that they talked about back then, they all turned out to be 100% true, because tech went higher for sure, Apple is still a winning company, we are surrounded with computers, smartphones and it's all tech and internet and websites, we still use yahoo mail every day and listen to yahoo finance and so on. Tech is cool and king. Still, the dot com bubble was bad and painful for the majority. See, everyone was right except for the ones who bought in at the high prices because of FOMO and/or the ones who didn’t sell at the top, and I think this applies to the majority. As you see now, those ‘top performers’ worked very well for those who bought in at the bottom or even half way to the top for swing trades (but that was just before you heard about them and not really any time later). So, the problem is that no one ever knows when is the top of a bubble or of any kind of run up that is driven by sentiment if it’s not a slow and steady growth corresponding both the fundamentals and financials in other words the real growth of a company. So the solution is to better find one that is trusted and/or have future and not going bankrupt soon and is beaten down to the ground. That’s when you buy in. Warren teaches this too, but this is my own thinking and just a coincidence that the old man says it too. So, I reveal here all my stocks and investment picks that I either bought and/or had planned or advised to buy so far with my first entry prices during 2020 (not placed in order of any sort, but just random). The majority are investments for 3-5 years the exceptions are the swing trades: TSLA again @ $358 (pre split); NYMT @ $1; IVR anywhere below $4; NIO anywhere below $5 (swing trade); HEXO @ $0.74 (pre split); ASTC @ $1.82 (swing trade); CDEV @ $1; LMND @ $47; TXMD @ $1.2; LXRX @ 1.93; GNW @ $3.26 (swing trade); WPG @ $1 (pre split); CRSP @ $60; gold below $1700; AAL @ $10 (swing trade); AMC @ $2.84 (swing trade); BTC @ $5500 for investment (and was swing trade too, from $7000 to $9000 because I had to pay property tax and did it from the profit).
NASDAQ:TXMDLong
by janfoux
2
Random Pick of The Week | $AKBA BioTechWelcome to the first "Random Pick of The Week", where I will randomly select a ticker to chart based on comments posted below or sent via direct message. Want a technical breakdown? - Follow Me - Smash Like - Comment 1 Ticker Todays's Pick: AKBA / Akebia Therapeutics Inc. Looking at the great scheme of things, we can see that AKBA has been in a steady downtrend for the last 5 years with only a few points of high demand. We've seen some massive leaps throughout the last 5 years, which is as expected knowing that we are trading biotech. We look like we will sit in a wedge up toward the start of 2021, leaving us with sideways movement (-+8%) until. We look for a breakout and retest of this wedge if bulls have any hope of any run into the New Years'. If we break out, we have $3.95 set as a short-term target and $7 as our long-term. We must watch $2.75/$2.70 as our weekly support, if lost look to short toward $2.10/.20. FYI: Ignore the green box, it decided to change angles last second. DCJ | Happy Holidays
NASDAQ:AKBALong
by DotcomJack
Big Rock Partners Acquisition Corp Announces Merger with NeuroRxBig Rock Partners Acquisition Corp. Announces Merger with NeuroRx, Inc. Combined Company to Have an Estimated Post-Transaction Equity Value in Excess Of $500 Million (Excluding Potential Earnout Payments), Assuming A Share Price Of At Least $10.00 Per Share NeuroRx, Inc. is a clinical stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of COVID-19 (RLF-100 or "ZYESAMI™ (aviptadil)") and Bipolar Depression (NRX-100, 101) The transaction is expected to occur in the first or second quarter of 2021. Under the terms of the transaction, Big Rock will issue to NeuroRx's current equity holders an aggregate of 50 million shares of Big Rock common stock for their interests in NeuroRx ubject to certain conditions, an aggregate of 25 million additional shares of Big Rock common stock will be issued to NeuroRx pre-merger equity holders if, prior to December 31, 2022, (1) RLF-100 receives emergency use authorization by the FDA and (2) the FDA accepts the Company's filing of its application to approve RLF-100. In addition, subject to certain conditions, a $100 million cash earnout may be payable to NeuroRx pre-merger equity holders if, prior to December 31, 2022, either (1) FDA approval of the Company's COVID-19 Drug is obtained and the Company's COVID-19 Drug is listed in the FDA's "Orange Book" or (2) FDA approval of the Company's Antidepressant Drug Regimen is obtained and the Company's Antidepressant Drug Regimen is listed in the FDA's "Orange Book". finance.yahoo.com
B
by AlenCiken
2
CYCC Announces at-the-market $7 Million Strategic InvestmentCyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures Cyclacel Pharmaceuticals has entered into a definitive securities purchase agreement with Acorn Bioventures, LP, a biotech-focused fundamental investor. - Strategic investment from single biotech-focused institutional investor - - Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors - Acorn Bioventures has agreed to purchase in a registered direct offering 485,912 shares of common stock and 237,745 shares of newly designated Series B Preferred Stock (convertible into shares of common stock at a ratio of 1:5), and in a concurrent private placement, warrants to purchase 669,854 shares of common stock, for aggregate gross proceeds of approximately $7 million. The warrants will be exercisable beginning twelve months following the date of issuance, will expire on the five-year anniversary of the date of issuance, and have an exercise price of $4.13 per share. finance.yahoo.com
NASDAQ:CYCC
by AlenCiken
ILMN Stocks for 2021 Looking to Illumina price now that earnings are knocking at the door, as you can see we are in a kind of Rangin Zones for ILMN price, anyway his Fundamental for a long term stil realy valuable in my opinion, We traced some of the most importants keys levels as support and resistence adding just the last trendline we are looking for a breakout or a confirm as a support. Biotechnologys industries are supposed to grow but we always recommend to investors for attention because this market is getting bigger day by day and competitors could be able to take a slice from this Big Profitable Pie.
NASDAQ:ILMNLong
by TheOmahaTrader
JAGX Signs Second Agreement for $6 Mil Non-dilutive FinanciningJaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream Jaguar Health, Inc. has signed an agreement (the "Agreement") with a secured lender (the "Lender") for a non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the Lender for an aggregate purchase price of $6 million (the "Royalty Purchase Price") a royalty interest entitling the Lender to receive 2.0x the Royalty Purchase Price of future royalties of Mytesi® (crofelemer) and lechlemer and certain up-front license fees and milestone payments from licensees and/or distributors as well as any interest, fees, and charges in accordance with the terms set forth in the Agreement (the "Royalty Repayment Amount"), and to pay interest on the Royalty Repayment Amount at the rate of ten percent per annum until the same is paid in full. No royalty payments due for 18-24 months Jaguar intends to use the proceeds to support regulatory activities associated with the Company's development pipeline This $6 million royalty financing transaction follows an earlier $6 million royalty transaction consummated in October 2020 with an affiliate of the Lender. We may consider entering into similar agreements in the future and of course business development relationships as additional sources of non-dilutive funding." finance.yahoo.com
NASDAQ:JAGX
by AlenCiken
#Ultimovacs $ULTI announce FOURTH randomized phase 2 trial FOCUSNote that information about the third study is still expected before year end. Ultimovacs ASA – Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab Oslo, 22 December 2020: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), today announced the initiation of FOCUS, a Phase II randomized clinical trial that will evaluate the Company’s proprietary universal cancer vaccine, UV1, in 75 patients with recurrent or metastatic head and neck cancer who will be treated with standard of care therapy pembrolizumab. The trial will be conducted at 10 sites across Germany and led by principal investigator Prof. Mascha Binder, M.D., Medical Director and Head of the Immunological Tumor Group at University Medicine Halle, Germany, who is a renowned oncology clinician and researcher specializing in the analysis of immuno-oncology treatments and their interaction with tumor tissues. The FOCUS trial is Ultimovacs’ fourth Phase II clinical trial with UV1 and comes in addition to the collaboration Phase II trial announced in May 2020. “We continue to strategically expand our clinical development program for our proprietary cancer vaccine, not only by testing UV1 in additional cancer indications with critical need, such as head and neck cancer, but also by collaborating with clinicians like Professor Binder who can provide us with unique insights,” stated Jens Bjørheim, Chief Medical Officer at Ultimovacs. “Professor Binder and her team are well-recognized experts who will increase our understanding of UV1’s mechanism of action and contribute data on anti-tumor activity induced by UV1 vaccination.” The FOCUS (First-line metastatic Or recurrent HNSCC/Checkpoint inhibitor UV1 Study) Phase II trial is an investigator-sponsored, randomized Phase II clinical trial that will recruit patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma across 10 clinical sites in Germany. The trial will evaluate the addition of UV1 to a standard of care treatment with PD-1 checkpoint inhibitor pembrolizumab as compared to pembrolizumab monotherapy. A total of 75 patients indicated for treatment with pembrolizumab will be enrolled in the FOCUS study, randomized 2-to-1 so that 50 patients will receive UV1 and pembrolizumab and 25 patients will receive pembrolizumab alone. The primary endpoint of the study is the progression-free survival rate at 6 months, and planned readout of topline results is expected in 2023. The FOCUS Phase II trial is partially supported through an innovation grant of up to NOK 16 million from the Norwegian Research Council and will not require Ultimovacs to secure additional financing at this stage. “This clinical trial is the extension of an earlier collaboration with Ultimovacs that introduced me to the therapeutic potential of the UV1 approach,” commented Professor Mascha Binder, M.D., Medical Director and Head of the Immunological Tumor Group at University Medicine Halle. “I am excited to apply my own insights as well as my team’s expertise to this trial with the goal of potentially providing head and neck cancer patients with better treatment options.” “We have continued to build momentum in our broad clinical development program with the start of the FOCUS study, representing the important opportunity to test UV1 in combination with pembrolizumab in a randomized setting for the first time,” said Carlos de Sousa, Chief Executive Officer at Ultimovacs. “We welcome the funding provided by the Norwegian Research Council, which supports our ability as a small biotechnology company to conduct four Phase II trials in parallel and evaluate UV1 in different indications with more than 450 patients and as part of various treatment combinations.” Dr. de Sousa added: “Although we have signed our agreement with the lead investigator for our previously announced third Phase II clinical trial, we will need to wait for the investigator and the pharmaceutical partner to finalize the signature process for their agreement before we can provide full details, which we expect to do before year end.”
ULong
by savepiginvest
]ImmunityBio and NantKwest to MergeImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company (agreement to merge in a stock-for-stock transaction.) Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms Together, ImmunityBio and NantKwest will have a broad, clinical-stage pipeline – including 13 assets in clinical trials and 11 in Phase II to III – as well as a robust early stage pipeline to address other difficult to treat cancers. Broad late-stage pipeline for solid tumors including bladder, lung, breast, and pancreatic in addition to infectious disease programs for HIV and COVID-19 Transaction Details The transaction is structured as a tax-free 100% stock-for-stock merger, with ImmunityBio to reverse merge with NantKwest. Under the terms of the agreement, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned. Upon completion of the transaction, on a fully diluted basis, ImmunityBio shareholders will own approximately 72% of the combined company and NantKwest shareholders will own approximately 28% of the combined company, on a fully diluted basis. The transaction, which is expected to close in the first half of 2021. Following the closing of the transaction, the combined company will assume the ImmunityBio name and continue to be listed on the NASDAQ exchange. However, the combined company ticker symbol is expected to be changed to IBRX. finance.yahoo.com ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort with 59% probability of patients maintaining complete response for at least 12 months Over 85% of patients in this study have avoided a cystectomy to date Breakthrough status for ImmunityBio’s superagonist Anktiva N-803 in this indication Biologics License Application filing anticipated in second half of 2021 finance.yahoo.com
N
by AlenCiken
4
Lilly to acquire Prevail for $22.50 per share in cash Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040 billion). Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease. Gene therapy is a promising approach with the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson's, Gaucher and dementia The acquisition of Prevail will bring critical technology and highly skilled teams to complement our existing expertise at Lilly, as we build a new gene therapy program anchored by well-researched assets. We look forward to completing the proposed acquisition and working with Prevail to advance their groundbreaking work through clinical development." finance.yahoo.com
P
by AlenCiken
2
Easy 10%er upcoming Consolidation at LQDA in range of their all time low after FDA issued the biotech company a CRL due to COVID restrictions. After speaking with regulators at the FDA, The company expressed this CRL had nothing to do with the underlying data. Options activity has been healthy. I believe price will increase from here, which is why I have started a position and continue to add on any meaningful dips (eg yesterday, the company issued PR for $200 mln mixed securities shelf offering) causing week hands to sell. Stop loss under previous low, friends. let’s go!! Disclaimer: this is not recommendation to buy or sell, this information is to be used for educational purposes only. Trade at your own risk.
NASDAQ:LQDALong
by follow_the_money
BioCardia Anticipates DSMB Feedback on Interim Data1. BioCardia Anticipates DSMB Feedback on Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial BCDA today announces that it anticipates data safety monitoring board (DSMB) verbal feedback by the end of December 15, 2020 on interim data from the Company’s pivotal Phase 3 CardiAMP Heart Failure Trial that is currently enrolling nationwide for infusion of BioCardia’s CardiAMP™ autologous cell therapy to the myocardium. The DSMB is then anticipated to provide its written feedback approximately 24 hours later. BioCardia plans to provide an announcement pre-market on December 17 , 2020 summnarizing the feedback and outlining the next resulting steps. The CardiAMP Heart Failure study has been approved by the FDA to enroll up to 260 patients at up to 40 centers. The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy in the treatment of patients with ischemic heart failure . The FDA has said that the trial qualifies as a pivotal trial to produce the primary data to support market registration for the CardiAMP cell therapy for this significant unmet clinical need. www.globenewswire.com 2. BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules today announced it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 16, 2020, subject to the satisfaction of customary closing conditions. finance.yahoo.com
NASDAQ:BCDA
by AlenCiken
2
Arvinas Nearly Doubles on Promising Cancer Drug ResultsArvinas Nearly Doubles on Promising Cancer Drug Results The test results show the Arvinas drugs' potential for treating breast and prostate cancer, Cantor said. Arvinas (ARVN) - Get Report shares blasted off Monday as Cantor Fitzgerald offered bullish comments on the biopharmaceutical company after it reported positive news on its breast and prostate cancer treatments. “For ARV-471, interim Phase 1 data show potential for best-in-class safety and tolerability, estrogen receptor (ER) degradation superior to that previously reported for the current standard of care agent (fulvestrant), and robust efficacy signals in heavily pretreated patients with locally advanced or metastatic ER positive / HER2 negative (ER+/HER2-) breast cancer,” the company said in a statement. The test results show ARV-471’s potential as the best-in-class potential estrogen receptor degrader, Cantor analyst Alethia Young wrote in a commentary cited by Bloomberg. The results are “very encouraging and demonstrated ARV-471 was active,” Young wrote. She has an overweight rating and a $66 price target on Arvinas. “The efficacy signals include one Response Evaluation Criteria in Solid Tumors (RECIST) confirmed partial response (PR), two additional patients with unconfirmed PRs, and a clinical benefit rate (CBR) of 42%,” Young said. Separately, Cantor said that “for ARV-110, the ongoing dose escalation portion of the Phase 1/2 trial in men with metastatic castration-resistant prostate cancer (mCRPC) has provided additional evidence of anti-tumor activity and patient benefit, including a prostate specific antigen reduction of more than 50% (PSA50) rate of 40% in a molecularly defined patient population.” Further, “Arvinas has initiated a Phase 2 dose expansion to explore a two-pronged development strategy, including the potential for accelerated approval in molecularly defined, late-line patients, and broader development in less-heavily pretreated mCRPC patients with fewer androgen receptor (AR)-independent mechanisms of tumor resistance,” Young said. Oppenheimer Upgrades Arvinas Inc. (ARVN) to Outperform, Following Clinical Update www.thestreet.com www.streetinsider.com
NASDAQ:ARVN
by AlenCiken
Solid Biosciences Announces $90 Million Private PlacementSolid Biosciences Announces $90 Million Private Placement Solid Biosciences has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions. The private placement includes new investors Suvretta Capital Management, LLC and Aspire Capital Fund, LLC and existing investors, including RA Capital Management, Perceptive Advisors, LLC, Bain Capital Life Sciences, EcoR1 Capital, LLC, Boxer Capital, and Ikarian Capital, LLC, as well as certain board members and executive officers. In this private placement, the Company is selling 24,324,320 shares of common stock at a price of $3.70 per share. The Company expects to use net proceeds from the private placement to fund research and development expenses, including the advancement of SGT-001, and for working capital and other general corporate purposes. finance.yahoo.com
NASDAQ:SLDB
by AlenCiken